Coherus Oncology (CHRS) FCF Margin (2013 - 2026)
Coherus Oncology (CHRS) posted FCF Margin of 470.24% for Q1 2026, down 113.39% sequentially from 220.36% in Q4 2025, and down 6827.0% YoY from 6.99% in Q1 2025.
Coherus Oncology (CHRS) FCF Margin (2013 - 2026) Analysis & Trends
Coherus Oncology has reported FCF Margin for 13 years, with the latest figure at 470.24% in Q1 2026.
- Quarterly FCF Margin fell 6827.0% year-over-year to 470.24% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 649.38% (up 53644.0% YoY) and the FY2025 annual result came in at 786.76%, up 89.0% from the prior year.
- FCF Margin declined to 470.24% in Q1 2026 per CHRS's latest filing, from 220.36% in the prior quarter.
- Over five years, FCF Margin peaked at 6111.66% in Q1 2024 and troughed at 1024.72% in Q3 2024.
- A 5-year average of 491.02% and a median of 84.65% in 2022 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2024 and 2025: FCF Margin surged 632402 bps in 2024, then slumped 651362 bps in 2025.
- Over 5 years, FCF Margin stood at 220.59% in 2022, then surged by 94 bps to 14.17% in 2023, then surged by 2710 bps to 369.95% in 2024, then slumped by 160 bps to 220.36% in 2025, then plunged by 113 bps to 470.24% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 470.24%, 220.36%, and 400.48% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 70.82% |
| 10 | Coherus Oncology | 220.61 Mn | 115.31 Mn | 10.07 Mn | -433.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -433.98% |
| Mar 31, 2026 | -470.24% |
| Dec 31, 2025 | -220.36% |
| Sep 30, 2025 | -400.48% |
| Jun 30, 2025 | 4,259.49% |
| Mar 31, 2025 | -401.96% |
| Dec 31, 2024 | 369.95% |
| Sep 30, 2024 | -1,024.72% |
| Jun 30, 2024 | 968.67% |
| Mar 31, 2024 | 6,111.66% |
| Dec 31, 2023 | -14.17% |
| Sep 30, 2023 | -72.82% |
| Jun 30, 2023 | -66.45% |
| Mar 31, 2023 | -212.37% |
| Dec 31, 2022 | -220.59% |
| Sep 30, 2022 | -82.66% |
| Jun 30, 2022 | -84.65% |
| Mar 31, 2022 | -90.93% |
| Dec 31, 2021 | -71.97% |
| Sep 30, 2021 | 16.30% |